Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolododekin alfa + cetrelimab
- Development stage
- Unknown
- Lead developer
- Ankyra Therapeutics
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral, Intravenous
01
Overview
Tolododekin alfa + cetrelimab is an investigational, intratumorally administered combination therapy undergoing phase 1 evaluation for advanced solid tumors (including cutaneous squamous cell carcinoma and non-small cell lung cancer). Tolododekin alfa (ANK-101) is an anchored interleukin-12 (IL-12) drug conjugate, where IL-12 is linked to aluminum hydroxide to ensure prolonged localization and activity within the tumor microenvironment, promoting localized immune activation while limiting systemic toxicity. Cetrelimab (JNJ-63723283) is a human monoclonal antibody that targets programmed cell death protein 1 (PD-1) to inhibit immune checkpoint pathways, thereby enhancing antitumor T-cell activity. The combination is intended to synergize immune activation (via anchored IL-12) and immune checkpoint inhibition (via PD-1 blockade), aiming for enhanced antitumor effects, especially in high-risk locally advanced or metastatic settings[2][5][6][7][10].
- Other names
- tolododekin alfa + cetrelimabANK-101 + cetrelimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on tolododekin alfa + cetrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolododekin alfa + cetrelimab.